Partners in PPID for Equine Veterinarians

Partners in PPID for Vets logo
You've probably noticed that more of your horse owners are interested in keeping their horses happy and healthy into their third and even fourth decades of life. This interest in maintaining older horses has led to increased awareness of pituitary pars intermedia dysfunction (PPID) and the desire to successfully manage the disease.

In fact, a new forum of leading clinicians and researchers in equine endocrinology was recently formed to share scientific knowledge and chart a course for the future in managing endocrine disease. The group convened for the first time at the 2011 Equine Endocrinology Summit (EES). Already the group has created a new PPID diagnostic protocol to help practitioners diagnose PPID in their patients. To view the new recommendations, click here.

If you'd like to keep in the loop about the latest information about PPID, you're invited to join Partners in PPID for Equine Veterinarians. Read more about the benefits of this free network and join below.

Benefits of joining the Partners in PPID for Equine Veterinarians community

You'll receive:

  • Access to free print or downloadable postcard mailers and in-clinic PPID education and support materials to use with your clients to promote awareness of the signs and treatment options for PPID
  • New recommended PPID diagnostic protocols and updates from leading endocrinologists
  • Real-life PPID case studies from top researchers and general practitioners
  • Newsletters with updated information on managing PPID
  • The latest information supporting use of PRASCEND® (pergolide mesylate), the only FDA-approved drug for managing PPID in horses and ponies1,2

Become a Partner

Please enter the following information in the fields provided. Click the Become a Partner button when you're finished. We'll send you a registration confirmation and other information you may have requested at the email address you provide.

* indicates required fields

Please fix these errors:

Important safety information

PRASCEND is for use in horses only. Treatment with PRASCEND has been observed to cause inappetance, with most cases being transient. Weight loss, lethargy, and behavioral changes may be observed in some horses. If severe, a temporary reduction of dose may be necessary. PRASCEND has not been evaluated in breeding, pregnant, or lactating animals. As PRASCEND is a dopamine agonist, it may interfere with reproductive hormones involved in these groups of animals. The concurrent use of dopamine antagonists should be avoided since these agents may diminish the effectiveness of PRASCEND. PRASCEND should not be used in horses with hypersensitivity to pergolide mesylate or other ergot derivatives. Refer to the package insert for complete product information.

References:

  1. PRASCEND® (pergolide mesylate) [package insert]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011.
  2. PRASCEND® (pergolide mesylate) [Freedom of Information Summary]. St Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2011.